- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01153217
Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In Hiv-1-Infected Subjects With Loss Of Bone Mineral Density
MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM TENOFOVIR TO ABACAVIR IN HIV-1-INFECTED SUBJECTS WITH LOSS OF BONE MINERAL DENSITY
Study Overview
Detailed Description
The prevalence of osteoporosis in HIV-infected patients could be more than three times greater compared with HIV-uninfected subjects, according to the results of a meta-analytical review of cross-sectional published studies. The analysis includes data from 884 HIV-infected patients and 654 HIV-uninfected controls. Sixty-seven percent of HIV population had reduced bone mineral density (BMD), of whom 15% had osteoporosis (OR of 6.4 and 3.7, respectively, compared with HIV-uninfected controls).
In the same meta-analysis, when authors evaluated the role of antiretroviral therapy (ART) on BMD, comparing 202 antiretroviral-naive with 824 ART-treated patients, patients on treatment had a 2.5-fold increased odds of prevalent reduced BMD and osteoporosis. And finally, when 410 non-protease inhibitor (PI)-treated HIV patients were compared with 791 patients receiving a PI-containing regimen, those on PIs had increased odds of reduced BMD and osteoporosis.
As well, other studies support data of an impaired BMD in HIV-infected patients after starting antiretroviral therapy. These results let us confirm that HIV itself and antiretroviral therapy contribute to decrease the BMD.
However, most of studies have not found any consistent drug-specific association with bone loss and controversial data with respect the effect of PIs have been published. The more evident finding with respect to this issue is the more pronounced decrease of BMD in patients during the first weeks of receiving a tenofovir (TDF)-containing regimen, probably by the effect of TDF on phosphorus balance and vitamin D metabolism.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08041
- Hospital de la Santa Creu i Sant Pau
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Lluita contra la Sida Foundation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients (=/+18 years old) having a diagnosis of HIV-1 infection.
- Current HAART including tenofovir plus emtricitabine/lamivudine plus a PI, a NNRTI or raltegravir started at least 12 months before.
- T-score ≤-2 measured by DEXA (within the last 6 months).
- Maintained undetectable plasma HIV-1 RNA (VL < 50 copies/mL) for at least 12 months.
- Absence of suspected or documented resistance mutations in the RT associated to abacavir.
- Voluntary written informed consent.
Exclusion Criteria:
- History of intolerance, toxicity or virological failure to abacavir.
- HLA B*5701 positive.
- Secondary osteoporosis/osteopenia (vitamin D or testosterone deficit, thyroid disease, …)
- Therapy with biphosphonates within the last 12 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Abacavir
Switch from tenofovir to abacavir
|
Switch from tenofovir to abacavir
Other Names:
|
No Intervention: tenofovir
Follow same ART regimen
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bone mineral density
Time Frame: From baseline to week 48
|
From baseline to week 48
|
t-score change
Time Frame: From baseline to week 48
|
From baseline to week 48
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
viral load
Time Frame: Evolution from baseline to week 48
|
Evolution from baseline to week 48
|
CD4 T lymphocytes count
Time Frame: Evolution from baseline to week 48
|
Evolution from baseline to week 48
|
Resistance test
Time Frame: If virological failure occurs
|
If virological failure occurs
|
Lipid parameters (total, HDL-, LDL-cholesterol and triglyceride levels)
Time Frame: Evolution from baseline to week 48
|
Evolution from baseline to week 48
|
Adverse Events
Time Frame: From baseline to week 48
|
From baseline to week 48
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OSTEOTENOFOVIR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on Switch from tenofovir to abacavir
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
University of Colorado, DenverCompletedHIV-1-infectionUnited States
-
National Institute on Media and the FamilyUniversity of Minnesota; Michigan State University; Iowa State University; Cargill and other collaboratorsCompletedObesity | OverweightUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedRheumatoid Arthritis | Uveitis | Crohn's Disease | SpondyloarthritisFrance
-
Calmy AlexandraCompletedAntiretroviral Therapy | HIV-1-infection | Maintenance TherapySwitzerland
-
ViiV HealthcareCompletedHIV Infection | Infection, Human Immunodeficiency Virus IUnited States, Spain, Germany, Canada, Belgium, Portugal, Italy, France, United Kingdom
-
Mahidol UniversityRecruitingRenal Insufficiency | TenofovirThailand
-
Centre de Recherches et d'Etude sur la Pathologie...Active, not recruiting
-
Quest Clinical ResearchGilead SciencesCompleted